Show simple item record

dc.contributor.authorKopp, Nadja
dc.contributor.authorDiaz, Diana
dc.contributor.authorAmacker, Mario
dc.contributor.authorOdongo, David O
dc.contributor.authorBeier, Konstantin
dc.contributor.authorNitsch, Cordula
dc.contributor.authorBishop, Richard P
dc.contributor.authorDaubenberger, Claudia
dc.identifier.citationVaccine Volume 28, Issue 1, 10 December 2009, Pages 261–269en_US
dc.description.abstractThe BM86 antigen, originally identified in Rhipicephalus (Boophilus) microplus, is the basis of the only commercialized anti-tick vaccine. The long-term goal of our study is to improve BM86 based vaccines by induction of high levels of tick gut binding antibodies that are also cross-reactive with a range of BM86 homologues expressed in other important tick species. Here we have used a BD86 derived synthetic peptide, BD86-3, to raise a series of mouse monoclonal antibodies. One of these mAbs, named 12.1, recognized BM86 homologues in immuno-histochemical analyses in four out of five tick species including R. (B.) microplus, Rhipicephalus (Boophilus) decoloratus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus. Our results indicate that broadly cross-reactive tick gut binding antibodies can be induced after immunization with a synthetic peptide derived from the protein BD86.en_US
dc.publisherUniversity of Nairobien_US
dc.subjectTick subunit vaccine development; Synthetic peptide; Immuno-histochemistry; Cross-reactivityen_US
dc.titleIdentification Of A Synthetic Peptide Inducing Cross-reactive Antibodies Binding To Rhipicephalus (boophilus) Decoloratus, Rhipicephalus (boophilus) Microplus, Hyalomma Anatolicum Anatolicum And Rhipicephalus Appendiculatus Bm86 Homologuesen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record